488 related articles for article (PubMed ID: 27866262)
1. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
[TBL] [Abstract][Full Text] [Related]
2. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
Esteves AR; Gozes I; Cardoso SM
Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydroxystilbene glucoside inhibits α-synuclein aggregation and apoptosis in A53T α-synuclein-transfected cells exposed to MPP
Zhang R; Sun F; Zhang L; Sun X; Li L
Can J Physiol Pharmacol; 2017 Jun; 95(6):750-758. PubMed ID: 28187263
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mortalin/GRP75/mthsp70 in the mitochondrial impairments induced by A53T mutant α-synuclein.
Liu FT; Chen Y; Yang YJ; Yang L; Yu M; Zhao J; Wu JJ; Huang F; Liu W; Ding ZT; Wang J
Brain Res; 2015 Apr; 1604():52-61. PubMed ID: 25665531
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells.
Parihar MS; Parihar A; Fujita M; Hashimoto M; Ghafourifar P
Int J Biochem Cell Biol; 2009 Oct; 41(10):2015-24. PubMed ID: 19460457
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease.
Bir A; Sen O; Anand S; Khemka VK; Banerjee P; Cappai R; Sahoo A; Chakrabarti S
J Neurochem; 2014 Dec; 131(6):868-77. PubMed ID: 25319443
[TBL] [Abstract][Full Text] [Related]
10. An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease1.
Vasquez V; Mitra J; Perry G; Rao KS; Hegde ML
J Alzheimers Dis; 2018; 66(2):453-460. PubMed ID: 30320583
[TBL] [Abstract][Full Text] [Related]
11. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells.
Perfeito R; Lázaro DF; Outeiro TF; Rego AC
Mol Cell Neurosci; 2014 Sep; 62():51-9. PubMed ID: 25109238
[TBL] [Abstract][Full Text] [Related]
12. The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.
Butler EK; Voigt A; Lutz AK; Toegel JP; Gerhardt E; Karsten P; Falkenburger B; Reinartz A; Winklhofer KF; Schulz JB
PLoS Genet; 2012 Feb; 8(2):e1002488. PubMed ID: 22319455
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease.
Xie W; Chung KK
J Neurochem; 2012 Jul; 122(2):404-14. PubMed ID: 22537068
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
[TBL] [Abstract][Full Text] [Related]
16. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
[TBL] [Abstract][Full Text] [Related]
17. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism.
Liu Z; Yu Y; Li X; Ross CA; Smith WW
Pharmacol Res; 2011 May; 63(5):439-44. PubMed ID: 21237271
[TBL] [Abstract][Full Text] [Related]
18. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux.
Marongiu R; Spencer B; Crews L; Adame A; Patrick C; Trejo M; Dallapiccola B; Valente EM; Masliah E
J Neurochem; 2009 Mar; 108(6):1561-74. PubMed ID: 19166511
[TBL] [Abstract][Full Text] [Related]
19. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of chondroitin sulfate on SH‑SY5Y cells overexpressing wild‑type or A53T mutant α‑synuclein.
Ju C; Gao J; Hou L; Wang L; Zhang F; Sun F; Zhang T; Xu P; Shi Z; Hu F; Zhang C
Mol Med Rep; 2017 Dec; 16(6):8721-8728. PubMed ID: 28990084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
